All In Biotech

Drug Trial Radar · NCT01578239

A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours

A Multicentre, Stratified, Open, Randomized, Comparator-controlled, Parallel-group Phase III Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours

Last checked: Nov 19, 2026Latest source record: Apr 4, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 231 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

231

Actual

Start

Sep 6, 2012

Primary completion

Jul 31, 2015

Study completion Jan 18, 2021

Sponsor

Lead sponsor
Advanced Accelerator ApplicationsNovartis (NVS)
Sponsor type
Industry
First posted
Apr 16, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a multicenter, stratified, open, randomized, comparator-controlled, parallel-group phase III study comparing treatment with Lutathera plus best supportive care (30 mg Octreotide LAR) to treatment with high dose (60 mg) Octreotide LAR in participants with metastasized or locally advanced, inoperable, somatostatin receptor positive, histologically proven midgut carcinoid tumours with progression despite LAR treatment.

Conditions

  • Carcinoid Tumor of the Small Bowel
  • Neuroendocrine Tumour

Interventions

  • Octreotide LARDrug

    In the experimental arm, 30 mg Octreotide LAR treatment was given to the participants until the end of study for symptom control purpose, unless the participant progressed or died. In the active comparator arm, 60 mg Octreotide LAR treatment was given to the participants every 4 weeks (i.m. injections) until the end of the study, unless the participant progressed or died.

  • 177Lu-DOTA0-Tyr3-OctreotateDrug

    Four administrations of 7.4 GBq (200 mCi) 177Lu-DOTA0-Tyr3-Octreotate administered at 8 +/- 1-week intervals, which could be extended up to 16 weeks to accommodate resolving acute toxicity.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS)Time frame: From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first until Primary Analysis cutoff date reached on 24July2015, assessed up to approximately 34 months

Locations

39 sites in 8 countries. Site status is shown where the registry gives one.

  • Cedars-Sinai Medical Center Samuel Oschin Cancer Center

    Los Angeles, California

  • Stanford Cancer Center

    Palo Alto, California

  • Moffitt Cancer Center

    Tampa, Florida

  • Northwestern Medical Faculty Foundation

    Chicago, Illinois

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Mayo Clinic

    Rochester, Minnesota

  • Duke University Medical Center

    Durham, North Carolina

  • Kettering Medical Center

    Kettering, Ohio

  • Perelman Center for Advanced Medicine

    Philadelphia, Pennsylvania

  • Henry-Joyce Cancer Clinic

    Nashville, Tennessee

  • University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Excel Diagnostics and Nuclear Oncology Center

    Houston, Texas

  • Digestive Oncology, Leuven Cancer Institute

    Leuven, Brabant Flamand, Belgium

  • Hôpital Beaujon AP-HP

    Clichy, France

  • Centre Hospitalier Lyon-Sud

    Lyon, Auvergne-Rhône-Alpes, France

  • Institut Gustave Roussy

    Villejuif, Île-de-France Region, France

  • Institut Claudius Regaud

    Toulouse, Midi-Pyrénées, France

  • Hotel Dieu/CHU Nantes

    Nantes, Pays de la Loire Region, France

  • Hôpital la Timone /CHU Marseille

    Marseille, Provence-Alpes-Côte d'Azur Region, France

  • Charité, Virchow-Klinikum, Gastroentrology, Hepatology & Endocrinology

    Berlin, Germany

  • Klinikum Rechts Isar, Nuclear Medicine

    Munich, Bavaria, Germany

  • Universitätsmedizin Mainz, Medizinische Klinik I Schwerpunkt Endokrinologie

    Mainz, Rhineland-Palatinate, Germany

  • Zentralklinik Bad Berka

    Bad Berka, Thuringia, Germany

  • Fondazione IRCCS Istituto Nazionale dei Tumori

    Milan, Italy

  • Università "Sapienza" di Roma, Facoltà di Medicina e Psicologia, Ospedale S. Andrea-Roma

    Roma, Italy

  • Istituto Oncologico Romagnolo per lo Studio dei Tumori

    Meldola, Emilia-Romagna, Italy

  • IEO Istituto Europeo di Oncologia

    Milan, Lombardy, Italy

  • Presidio Osp. Di Macerata

    Province of Macerata, The Marches, Italy

  • Azienda Ospedaliero - Universitaria Pisana (Presidio Ospedaliero S. Chiara)

    Pisa, Tuscany, Italy

  • Centro Hospitalar e Universitario de Coimbra

    Coimbra, Centro, Portugal

  • Instituto Português de Oncologia

    Porto, Norte, Portugal

  • Ramon y Cajal University Hospital

    Madrid, Spain

  • University Hospital of Bellvitge

    Hospitalet de Llobregat (Barcelona), Catalonia, Spain

  • Beatson Oncology Centre

    Glasgow, United Kingdom

  • Royal Free Hospital

    London, United Kingdom

  • Imperial College Healthcare Trust, Hammersmith Hospital

    London, United Kingdom

  • The Christie NHS foundation Trust

    Manchester, United Kingdom

  • University of Oxford

    Oxford, South East England, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.